ASCO 2023 | Combining lenvatinib & pembrolizumab for non-clear cell RCC: KEYNOTE-B61 study rationale

Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights the rationale behind combining lenvatinib and pembrolizumab as a first-line treatment for non-clear cell renal cell carcinomas (RCC) in the Phase II KEYNOTE-B61 (NCT04704219) study. While most clinical trials have focused on clear cell RCC, a significant portion of patients have non-clear cell histologies, which historically have not responded well to existing systemic therapies. The combination of lenvatinib and pembrolizumab has shown impressive efficacy in clear cell RCC, prompting interest in exploring its potential benefits for non-clear cell histologies as well. The study aims to determine whether this combination therapy can be effective in improving outcomes for patients with non-clear cell RCC, offering a new treatment option for this subgroup of kidney cancer patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.